The mission of the Career Development Program in squamous cell carcinoma of the head and neck (SCCHN) is to stimulate basic, translational and clinical research in head and neck cancer by recruiting new and established investigators in the area of head and neck cancer. The Career Development Program within the SPORE provides financial support for this mission, while the infrastructure of the SPORE provides a stimulating mentoring environment. The Career Development Program has the following objectives: 1) To recruit physicians, scientists and physician-scientists to direct their research efforts to the field of head and neck cancer;and 2) To train and guide these investigators through the process of developing into outstanding investigators in translational head and neck cancer research, including laboratory, clinical and population science. The faculty within the SPORE has a long-standing record in mentoring postdoctoral fellows, young scientists and research-oriented clinicians for careers in translational research. In the initial funding period, we supported seven junior faculty members in the Career Development Program, including three women, one of whom is African-American. All seven CDP-supported faculty have received peer reviewed funding in SCCHN and/or achieved objective career advancement. We will continue to support two promising translational investigators per year. The currently funded Research Training Grant in Head and Neck Oncology (T32) will serve as one source of research-oriented candidates to fill these positions. The SPORE-initiated recruitment of new faculty will consider candidates identified through the existing recruitment processes, with special emphasis placed on seeking minority candidates and women.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA097190-09
Application #
8541594
Study Section
Special Emphasis Panel (ZCA1-GRB-I)
Project Start
Project End
Budget Start
2013-07-01
Budget End
2014-06-30
Support Year
9
Fiscal Year
2013
Total Cost
$166,476
Indirect Cost
$86,635
Name
University of Pittsburgh
Department
Type
DUNS #
004514360
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213
Gleber-Netto, Frederico O; Zhao, Mei; Trivedi, Sanchit et al. (2018) Distinct pattern of TP53 mutations in human immunodeficiency virus-related head and neck squamous cell carcinoma. Cancer 124:84-94
Santuray, Rodell T; Johnson, Daniel E; Grandis, Jennifer R (2018) New Therapies in Head and Neck Cancer. Trends Cancer 4:385-396
Liu, Zhuqing; McMichael, Elizabeth L; Shayan, Gulidanna et al. (2018) Novel Effector Phenotype of Tim-3+ Regulatory T Cells Leads to Enhanced Suppressive Function in Head and Neck Cancer Patients. Clin Cancer Res 24:4529-4538
Lu, Shanhong; Concha-Benavente, Fernando; Shayan, Gulidanna et al. (2018) STING activation enhances cetuximab-mediated NK cell activation and DC maturation and correlates with HPV+ status in head and neck cancer. Oral Oncol 78:186-193
Nikiforova, Marina N; Mercurio, Stephanie; Wald, Abigail I et al. (2018) Analytical performance of the ThyroSeq v3 genomic classifier for cancer diagnosis in thyroid nodules. Cancer 124:1682-1690
Zhong, Qian; Liu, Zhi-Hua; Lin, Zhi-Rui et al. (2018) The RARS-MAD1L1 Fusion Gene Induces Cancer Stem Cell-like Properties and Therapeutic Resistance in Nasopharyngeal Carcinoma. Clin Cancer Res 24:659-673
Ma, Jing; Salamoun, Joseph; Wipf, Peter et al. (2018) Combination of a thioxodihydroquinazolinone with cisplatin eliminates ovarian cancer stem cell-like cells (CSC-LCs) and shows preclinical potential. Oncotarget 9:6042-6054
Hartman, Douglas J; Ahmad, Fahad; Ferris, Robert L et al. (2018) Utility of CD8 score by automated quantitative image analysis in head and neck squamous cell carcinoma. Oral Oncol 86:278-287
Pai, Sara I; Jack Lee, J; Carey, Thomas E et al. (2018) HLA class I antigen processing machinery (APM) component expression and PD-1:PD-L1 pathway activation in HIV-infected head and neck cancers. Oral Oncol 77:92-97
Shayan, Gulidanna; Kansy, Benjamin A; Gibson, Sandra P et al. (2018) Phase Ib Study of Immune Biomarker Modulation with Neoadjuvant Cetuximab and TLR8 Stimulation in Head and Neck Cancer to Overcome Suppressive Myeloid Signals. Clin Cancer Res 24:62-72

Showing the most recent 10 out of 310 publications